Please select the eligibility criteria that correspond to the clinical trial below.
Title: Estrogen in the Prevention of Atherosclerosis Trial
Brief Summary: The purpose of this study is to determine the effects of estrogen replacement therapy (ERT) on the progression of early atherosclerosis in healthy postmenopausal women without preexisting cardiovascular disease (CVD).


Options:
A: Inclusion Criteria:

* Postmenopausal female (serum estradiol less than 20 pg/ml)
* 46 to 80 years old
* Fasting LDL-C levels 130 to 210 mg/dL
* Triglyceride levels less than 400 mg/dL
* Current non-smoker

Exclusion Criteria:

* Clinical evidence of cardiovascular disease
* HDL-C level less than 30 mg/dL
* Fasting blood glucose greater than 200 mg/dL
* Previous hormonal replacement therapy (non-contraceptive) over 10 years duration and/or current use within 1 month
* Uncontrolled hypertension
* Untreated thyroid disease
* Renal insufficiency
* Clinical evidence of congestive heart failure
* Life threatening disease with prognosis less than 5 years
* Alcohol intake greater than 5 drinks per day (1 drink = 1 1/2 oz distilled spirits, 4 oz wine, or 12 oz beer) or substance abuse (intravenous drug abuse, cocaine use)
* History of estrogen dependent cancer or detected at screening or any other disorder precluding use of ERT
* Hot flashes greater than 5 per day which interfere with daily activity and preclude randomization to placebo.
B: Inclusion Criteria:

Eligible women will be those having any two of the following criteria

1. Amenorrhea of 6 months or more.
2. Serum follicle-stimulating hormone level of 30 IU/L or more.
3. Menopausal symptoms.
4. Age 48 years or older.

Exclusion Criteria:

1. Women older than 65 years.
2. Severe lupus activity at baseline (SLEDAI score, more than 30).
3. Use of estrogens within 3 months of the screening visit.
4. Serum creatinine of 2.0 mg/dL or more.
5. Hypertriglyceridemia 500 mg/dL or more.
6. Metabolic bone diseases.
7. Liver disease.
8. Untreated hyperthyroidism.
9. Recent thrombosis.
10. Malignancy.
11. Endometrial hyperplasia.
12. Undiagnosed uterine bleeding or cervical dysplasia
C: Postmenopausal women with angiographically-documented coronary disease. Approximately 70 percent minority
D: Inclusion Criteria:

* menses absent for at least 6 months and no more than 36 months
* good general health
* plasma FSH level greater than or equal to 35 mIU/ml
* estradiol levels \< 40 pg/ml
* normal mammogram within 1 year of randomization

Exclusion Criteria:

* use of hormone replacement or supplement within 3 months of randomization
* endometrial thickness \>5 mm by vaginal ultrasound
* in utero exposure to diethylstilbestrol (DES)
* current smoking \> 10 cigarettes/day
* obesity-body mass index \> 35
* history of clinical cardiovascular disease
* history of cerebrovascular disease
* history of thromboembolic disease
* coronary calcium score ≥ 50 units
* dyslipidemia-LDL cholesterol \>190 mg/dl
* hypertriglyceridemia-triglycerides \>400 mg/dl
* lipid lowering medication (statin, fibrate,or \> 500 mg/day of niacin)
* nut allergy (Prometrium includes peanut oil)
* uncontrolled hypertension-systolic BP \>150 and/or diastolic BP \> 95
* hysterectomy
* history of, or prevalent, chronic diseases including any cancer (other than basal cell skin cancers), renal failure, cirrhosis, diabetes mellitus, and endocrinopathies other than adequately treated thyroid disease
* known HIV infection and/or medications for HIV infection
* results of any safety laboratory test chemistries, (TSH, CBC, U/A) more than 20% abnormal

Answer: A